Dallas, TX -- (SBWIRE) -- 03/12/2015 -- The report "Ragweed Allergy – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Ragweed Allergy. The pollen from ragweed causes allergy symptoms in many people. These symptoms include sneezing, runny or stuffy nose, and itchy throat. Ragweeds are weeds that grow throughout the United States. They are most common in the Eastern states and the Midwest. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/ragweed-allergy-pipeline-review-h1-2015-market-report.html.
This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects.
Companies discussed in this report include:
- Allergy Therapeutics plc
- Anergis SA
- Biomay AG
- Circassia Pharmaceuticals plc
- Immunomic Therapeutics, Inc.
- Stallergenes S.A.
Drugs profiled discussed in this report include AllerR, BM-34, Drug for Ragweed Pollen Allergy, Multi-LAMP-Vax, PL-101, Pollinex Ragweed, ragweed hypoallergenic vaccine, Ragweed-SPIRE. Order a copy of this report at (Prices start at US $ 2000 for a single user PDF) http://www.rnrmarketresearch.com/contacts/purchase?rname=310151.
Featured News & Press Releases:
- Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR
- Dec 08, 2014: Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study
- Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting
- Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine
- Mar 07, 2012: Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results
- Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
List of Tables
Number of Products under Development for Ragweed Allergy, H1 2015 7
Number of Products under Development for Ragweed Allergy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Comparative Analysis by Unknown Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Ragweed Allergy - Pipeline by Allergy Therapeutics plc, H1 2015 15
Ragweed Allergy - Pipeline by Anergis SA, H1 2015 16
Ragweed Allergy - Pipeline by Biomay AG, H1 2015 17
Ragweed Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015 18
Ragweed Allergy - Pipeline by Immunomic Therapeutics, Inc., H1 2015 19
Ragweed Allergy - Pipeline by Stallergenes S.A., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Ragweed Allergy Therapeutics - Recent Pipeline Updates, H1 2015 37
Ragweed Allergy - Dormant Projects, H1 2015 39
Ragweed Allergy - Discontinued Products, H1 2015 40
Explore more reports on Allergy Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/allergy-drugs.